Pfizer Consumer Healthcare Ltd - परिणामों की खोज

pfizer consumer healthcare div. of pfizer new zealand ltd - glucose monohydrate; sodium chloride - tablet - 190mg/450mg - active: glucose monohydrate sodium chloride

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

pfizer-biontech covid-19 vaccine, bivalent- original and omicron ba.4/ba.5 injection, suspension

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj), famtozinameran (unii: jsv288q5cv) (famtozinameran - unii:jsv288q5cv) - pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5) is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 5 years of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5), hereafter referred to as pfizer-biontech covid-19 vaccine, bivalent, supplied in a multiple dose vial with an orange cap and a label with an orange border, which is authorized for use in individuals 5 through 11 years of age. the vial labels state: age 5y to <12y. the carton labels state: for age 5 years to <12 years. do not administer pfizer-biontech covid-19 vaccine, bivalent to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine or the pfizer-biontech covid-19 vaccine, bivalent [

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

celecoxib pfizer

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 400mg; - capsule - 400 mg - active: celecoxib 400mg excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate tekprint green sb-4027 titanium dioxide - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

lyrica (pfizer)

pharmacy retailing (nz) ltd t/a healthcare logistics - pregabalin 100mg; - capsule - 100 mg - active: pregabalin 100mg excipient: colloidal silicon dioxide gelatin iron oxide red lactose monohydrate maize starch purified talc purified water sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide